PEG-intron [peginterferon alfa-2b] plus Rebetol [ribavirin] for the treatment of subjects with chronic hepatitis C who failed to respond to previous combination therapy (any alpha interferon treatment in combination with ribavirin)

Trial Profile

PEG-intron [peginterferon alfa-2b] plus Rebetol [ribavirin] for the treatment of subjects with chronic hepatitis C who failed to respond to previous combination therapy (any alpha interferon treatment in combination with ribavirin)

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Apr 2017

At a glance

  • Drugs Peginterferon alfa-2b (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 28 Mar 2011 Actual initiation date for the extension trial [NCT00049842] is October 2002 actual patient number is 540.
    • 28 Mar 2011 Tial status for the extension trial [NCT00049842] is completed.
    • 28 Mar 2011 Actual end date for the extension trial [NCT00049842] is October 2009
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top